Healthcare
Live Price
Offline$0.25
+0.00% today
1Y Change
-16.67%
Window
Jun 26, 2025 → Jun 25, 2026
Coverage: 250 bars · Jun 26, 2025 → Jun 25, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CytoDyn Inc. (CYDY) is a Healthcare stock with a market cap of $440.00M and listed on OTC. The stock last traded around $0.25 and down 16.7% across the available one-year price window (Jun 26, 2025 → Jun 25, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +103.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +103.6%, free cash flow +20.2% with operating margin 355.6% and ROIC 104.3%. Stock Foundry combines CYDY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CYDY
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CYDY Max Drawdown
-37.84%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CYDY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$174.0M
+17.5% YoY
Free Cash Flow
-$117.7M
-51.4% YoY
Revenue Growth
+0.0%
EPS Growth
+103.6%
Gross Margin
0.3%
Net Margin
655.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | -6M | 0 | 0 | 266K | 0 |
| Gross Profit | -18K | -29K | -175K | 213K | -2M |
| Operating Income | 11M | -18M | -41M | -145M | -105M |
| EBITDA | 9M | -18M | -40M | -195M | -93M |
| Net Income | 4M | -50M | -80M | -211M | -174M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12M | 3M | 3M | 4M | 34M |
| Total Assets | 18M | 11M | 11M | 29M | 132M |
| Total Liabilities | 114M | 128M | 121M | 124M | 153M |
| Shareholder Equity | -96M | -117M | -110M | -94M | -21M |
| Total Debt | 27M | 30M | 35M | 37M | 63M |
| Net Debt | 15M | 27M | 33M | 33M | 30M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
118M
-51.3% YoY
Capital Expenditures
122K
Free Cash Flow
118M
-51.4% YoY
Key ratios
Gross Margin
0.3%
Operating Margin
355.6%
Net Margin
655.7%
ROE
37.0%
Debt / Equity
-0.26x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.